Abstract: A display module includes a display panel and a peripheral region. The peripheral region includes a bendable fan-out region including a panel bonding portion and a driving chip; a flexible circuit board, including a first and a second conductive layers, and a substrate. The first conductive layer includes a first and a second bonding portions, and a connection portion; the second conductive layer is located on a side of the first conductive layer and at least partially overlaps with the first bonding portion; the first and the second conductive layers are connected through a via hole penetrating through the substrate; an end of the flexible circuit board is bonded to the panel bonding portion through the first bonding portion, and the second bonding portion is bonded to a control circuit board; and a conductive protection layer, covering the driving chip and connected to the second conductive layer.

Abstract: Disclosed are a pixel circuit and a display panel. The pixel circuit includes a Light emitting device, a Data signal write-in module, a Driving transistor, a Compensation module, a First initialization module, and a Light emitting control module. The first initialization module is electrically connected to the compensation module and electrically connected to the gate of the driving transistor through the compensation module. When the voltage level of the gate of the driving transistor, the number of the transistors connected to the driving transistor could be reduced.

Abstract: A pixel circuit, a display panel and a control method are disclosed. The pixel circuit includes a light-emitting device, a driving module, and a light-emitting control module. By inserting the corresponding number of black frame insertion pulses into the light-emitting control signal during the early light-emitting stage and the late light-emitting stage of one frame, the difference between the sum of the light-emitting currents in the early light-emitting stage of said frame and the sum of the light-emitting currents in the late light-emitting stage of said frame can be reduced, and the perceived brightness difference in one frame can be effectively reduced, so as to improve the screen flickers.

Abstract: This application relates to communicating information between communication devices. A channel coding method is disclosed. A communication device obtains an input sequence of K bits. The communication device encodes the input sequence using a low density parity check (LDPC) matrix H, to obtain an encoded sequence. The LDPC matrix H is determined according to a base matrix and a lifting factor Z. The base matrix includes m rows and n columns, m is greater than or equal to 5, and n is greater than or equal to 27. The lifting factor Z satisfies a relationship of 22*Z?K. According to the encoding method provided in the embodiments, information bit sequences of a plurality of lengths can be encoded for transmission between the communication devices.

Abstract: A display module and an electronic device are provided. The display module includes a display film layer, a heat dissipation film layer, a support plate and an elastic thermal conductive sheet. The display film layer and the heat dissipation film layer include a flat area and bending areas, and an angle exists between a tangent of a curved surface formed by the bending areas and a plane where the flat area is located. The display film layer is stacked on a first surface of the heat dissipation film layer. The support plate is connected to a position where the flat area of a second surface of the heat dissipation film layer is located, and the elastic thermal conductive sheet is connected to a position where the bending areas of the second surface of the heat dissipation film layer are located. The first surface and the second surface are opposite surfaces.

Abstract: A hydrophilic silica/polymer blend is provided comprising (a) a hydrophilic silica powder; and (b) a thickening polymer powder, comprising (i) structural units of C4-8 alkyl (meth)acrylate monomer; (ii) structural units of (meth)acrylic acid monomer; (iii) structural units of (methoxy) poly(ethylene glycol) (meth)acrylate monomer; and (iv) structural units of multiethylenically unsaturated monomer; wherein the weight ratio of hydrophilic silica powder to thickening polymer powder in the hydrophilic silica/polymer blend is 1:9 to 9:1. Also provided are personal care compositions containing same and methods of using same.

Abstract: The present disclosure relates to a ropivacaine suspension injection, and a preparation method therefor. Specifically, the ropivacaine suspension injection of the present disclosure comprises ropivacaine and a pharmaceutically acceptable excipient, wherein the median particle size D50 of the suspension injection is within the range of 1 ?m to 40 ?m. The ropivacaine suspension injection of the present disclosure can continuously release a drug in vivo, and has an analgesic effect of no less than 12 h, preferably, an analgesic effect of no less than 24 h, and more preferably, an analgesic effect of no less than 72 h.

Abstract: This application provides a molecular property model training method performed by an electronic device. The method includes: obtaining a plurality of pieces of first sample data associated with a plurality of chemical reactions; performing forward propagation on a plurality of pieces of first molecule data of the plurality of pieces of first sample data in a first encoding network to obtain a first encoding feature of each first molecule data; determining an uncertainty loss of the plurality of chemical reactions based on the first encoding features of the plurality of pieces of first molecule data of the plurality of pieces of first sample data and indicator data of each chemical reaction; performing backward propagation processing on the uncertainty loss in the first encoding network to obtain an updated first encoding network as a molecular property model, the molecular property model being used for determining a property of a target molecule.

Abstract: A parameter processing method and apparatus for a virtual camera. The method includes obtaining a camera parameter of a first virtual camera in a virtual scene, the first virtual camera having a binding relationship with a physical camera in a real scene and the physical camera being configured to obtain image data of an object in the real scene, smoothing the camera parameter of the first virtual camera to obtain a target camera parameter; and configuring a second virtual camera in the virtual scene and adjusting a camera parameter of the second virtual camera based on the target camera parameter to obtain an adjusted second virtual camera, a focus of the second virtual camera corresponding to a focus of the first virtual camera, wherein the adjusted second virtual camera is configured for rendering based on the image data to obtain an image of the virtual scene comprising the object.

Abstract: The present invention provides a composition comprising an antiviral agent and a C—X—C chemokine receptor type 4 (CXCR4) antagonist, and methods for using the same. Compositions and methods of the invention can be used to treat viral infection, immune disorders (e.g., rheumatoid arthritis), pulmonary fibrosis, or any other clinical condition associated with abnormal expression (e.g., overexpression and/or upregulation) of CXCR4. Compounds of the invention can also be used in stem cell therapeutics.

Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.

Abstract: The present invention provides a composition comprising a therapeutic agent and a C-X-C chemokine receptor type 4 (CXCR4) antagonist, and methods for using the same. Compositions and methods of the invention can be used to treat cancer, viral infection, immune disorders (e.g., rheumatoid arthritis), pulmonary fibrosis, or any other clinical condition associated with abnormal expression (e.g., overexpression and/or upregulation) of CXCR4. Compounds of the invention can also be used in stem cell therapeutics.

Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.

Abstract: Reactor configurations may include one or more staged inlets and/or one or more staged outlets for gaseous and solid feedstocks. In one embodiment of the present disclosure, a reactor design for gas-solid reaction with one or more additional outlet for gas and/or solid phase is provided. In yet another embodiment, the design for a gas-solid reactor with one side inlet and two outlets for gas phase is described. In one embodiment, a reactor design with pairs of inlet and outlet for both gas and solid phase is provided. In another embodiment, a reactor design with one or more side inlets but only one outlet for gas phase is provided. In yet another embodiment, a reactor design with two inlets at the top/bottom of reactor and two side outlets for gaseous phase is described. In yet another embodiment, a reactor design with one or more side inlets and outlets for both gas and solid phases is provided.

Abstract: Provided in the present application is a humanized and multifunctional CD3 antibody; a heavy chain variable region of the CD3 antibody comprised herein contains the amino acid sequence of any one of SEQ ID NOs: 1-3 or a variant sequence thereof; and a light chain variable region thereof contains the amino acid sequence of any one of SEQ ID NOs: 26-28 or a variant sequence thereof. Further provided in the present application is a multifunctional antibody comprising (a) a light chain-heavy chain pair that has specificity for tumor cells or microorganisms; and (b) a fusion peptide that comprises a single-chain variable fragment and an Fc fragment having a CH2 domain and/or a CH3 domain, the fusion peptide having specificity for immune cells. The antibodies provided in the present application have improved biological activity, thermal stability and/or acid resistance.

Abstract: The present invention relates to the technical field of lighting for plant, and in particular, provides a multi-reflection panel lamp. The multi-reflection panel lamp includes a fixing frame, a plurality of panel lamps, and a plurality of reflectors. The plurality of panel lamps are embedded in the fixing frame parallel to each other. The reflectors and the panel lamps are parallelly disposed on the fixing frame. Compared to other panel lamps, in the present invention, reflectors are disposed between panel lamps to reflect, a plurality of times by using a multi-refraction mechanism of the reflectors of the panel lamps, rays of light emitted by the panel lamps, so that plants are irradiated with the rays of light at various angles, thereby improving lighting intensity and uniformity and ensuring normal growth of the plants.

Abstract: The present invention relates to a bispecific antibody, which is a tetravalent symmetrical bispecific antibody with a structure of F(ab)2-(Fv)2-Fc and comprises two identical fusion heavy chains and two identical fusion light chains.

Abstract: The present application discloses a supported PtZn intermetallic alloy catalyst, a method for preparing the same and application thereof. The catalyst uses SiO2 as a support and Zn as a promoter, and a small amount of active component Pt is supported; the weight percentage of Pt is 0.025%-1%, and the weight percentage of Zn is 0.025%-1.7%, a co-impregnation method is adopted in preparation, the SiO2 support is impregnated in aqueous solution of chloroplatinic acid and zinc nitrate, and then drying and high-temperature reduction are performed to obtain a PtZn/SiO2 catalyst. The catalyst has the advantages of high activity, high stability, low price and low toxicity. The catalyst provided by the present application is applicable to preparation of alkene through short-chain alkane dehydrogenation, in particular to preparation of propylene through propane dehydrogenation in a hydrogen atmosphere.

Abstract: A radiator and a plant illumination lamp containing the radiator. The radiator includes a heat-radiating baseplate configured for fixing a heat source, and heat-radiating side plates connected to the heat-radiating baseplate. The heat-radiating side plates each are provided with a plurality of heat-exchanging through grooves running through the heat-radiating side plates. The heat-exchanging through groove forms a heat potential difference, so that under the influence of the heat potential difference, the cold air outside the radiator passes through the heat-exchanging through groove on the heat-radiating side plates, and then flows out through a hot air chamber and an air outlet at an upper end of the hot air chamber after exchanging heat with the heat-exchanging through groove on the heat-radiating side plates, so as to form a strong natural air convection.

Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.